Good morning and welcome to Nextmune. Nextmune Second Quarter Earnings Call 2026. I am Olli, Group CEO, and together with me, I have our CFO, Carly Boudry, presenting our results for the second quarter. We continue building upon a good start of the year and report our second quarter with strong revenue and earnings growth as well as margin expansion. Our double-digit growth in the quarter is well ahead of the global animal health market. Coupled with strong adjusted EBITDA growth. We have also closed four acquisitions year-to-date and continue to advance our M&A pipeline with active discussions across all four segments. We have also achieved recognition for our ESG achievements with a new 'AAA' ESG rating from MSCI.
Turning to the numbers in a bit more detail. We report 17% revenue growth and reach €121.6 million in revenue in the second quarter. Organic growth was 12%, with double-digit growth in Specialty Pharma, MedTech, and Veterinary Services. Our three largest segments saw a 6% contribution from acquisitions. And we had a 1% negative impact from currency movements. Adjusted EBITDA grew 17% to €29.7 million, with strong earnings growth across all four segments. Margin improved to 24.5%, driven by the consolidation of acquired businesses in the MedTech dental segment. Moving into Specialty Pharma, the segment delivers another strong quarter with organic growth of 14%. All four therapeutic areas deliver solid growth, and the strongest contribution in this quarter comes from Specialty Pharmaceuticals and specialized nutrition. We completed another successful sales campaign together with a US retailer. A similar campaign took place in the third quarter of 2025. These campaigns make growth vary between quarters, but the underlying business momentum continues. Good. During the quarter, we also launched 25 new products and opened our new R&D hub in France focused on the development of biological pharmaceuticals. Adjusted EBITDA grew 13% to €15.4 million, and we maintain a strong margin at 30.1%. Before we move on to the other segments, in our last quarter presentation, we gave you a short business snapshot about our MedTech dental platform and veterinary services' upcoming market expansion.
In this quarter, we will continue our series of business snapshots by providing more insights into our innovation work within Specialty Pharma.
Thank you Olli, and let me spend a few minutes on innovation, as I have had the pleasure for the last couple of months to be close to the Specialty Pharma team and segment, working as ad interim responsible for the Specialty Pharma segment. So, innovation is really at the heart of Nextmune's Specialty Pharma growth strategy. Innovation is one of the four pillars of our strategy. We focus on identifying unmet clinical needs and bringing differentiated products to market through internal R&D, scientific collaborations, and selective partnerships. This approach is delivering consistent output. Over the last 12 months, we've launched 75 new products and have more than 60 additional products in the pipeline. These products span multiple therapeutic areas and technologies, creating a balanced and sustainable innovation engine. As you can see from the quarterly launch cadence, innovation remains a continuous process, supporting long-term organic growth and reinforcing our leadership positions in attractive specialty markets. Let me now make our innovation strategy a little bit more tangible by looking at two of our therapeutic areas: allergy and specialty pharmaceuticals in allergy. Our ambition is to further strengthen our position as a global leader in veterinary allergology. PAX2 is a great example of that, and a further innovation of the PAX2 Pet Allergy Explorer that we launched three years ago by incorporating an additional 25 novel allergens identified by Nextmune. We're further enhancing the clinical value of our diagnostics platform, with commercial launch targeted around one of the world's largest dermatology congresses.
ESVD-ECVD. In the autumn of 2026, in Specialty Pharmaceuticals, our ambition is to build a differentiated, compounded drugs portfolio through internal innovation, combined with partnerships with biotech companies and leading universities. One example of how we're delivering on this ambition is through our newly established division. Nextmune Bio. Nextmune Bio significantly strengthens our biological capabilities through a dedicated R&D team, a development facility, and an established biologics pipeline, creating a platform for future prescription innovation across therapeutic areas. Our innovation strategy extends beyond prescription diagnostics to prescription drugs and our entire OTC portfolio, where we continue to develop differentiated products addressing unmet needs in dermatology. Our ambition is to strengthen our leading position in skin and ear care through continued innovation, while leveraging that expertise to expand into adjacent therapeutic areas. A good example is IryLac, our first ophthalmology OTC product. It expands our presence into eye care with a preservative-free formulation designed to restore tear film stability and improve patient comfort. Our ambition is to continue building a differentiated portfolio of nutritional solutions based on scientific evidence and targeted innovation. A good example is UNA-10, a microbiota-focused supplement supporting gut health. Its differentiated formulation enables targeted release and reflects our focus on translating science into products that address real clinical needs. Across our therapeutic areas. Our approach is consistent: focused R&D investments, a deep understanding of unmet clinical needs, and a steady pipeline of differentiated innovations. Together, these capabilities provide a strong foundation for sustainable organic growth in specialty pharma.
Thank you very much.
Moving on to MedTech, the segment returned to double-digit growth of 11%, with double-digit growth in both the dental and orthopedic businesses.
As expected, our US orthopedic business returned to growth on the back of our consistent efforts to strengthen commercial performance and operations despite unchanged market conditions. Our focus on education to unlock long-term market growth in both orthopedics and dental remains. And we educated over 1,300 veterinarians in the quarter. Adjusted EBITA grew 27% to €11.2 million, and adjusted EBITA margin improved to 25.8%, mainly driven by the consolidation of acquired businesses in the veterinary dental part of the segment. Moving on to Veterinary Services, the segment continues its momentum and delivered a strong organic growth of 10%, with continued momentum in new member growth and strategic partnerships. At the end of the quarter, we reached 11,900 members across four continents. Adjusted EBITDA grew 18% and adjusted EBITDA margin reached 28.2%. As expected, this was somewhat lower than the previous year due to mixed effects from acquisitions and our communicated growth investments in new markets and services. Looking into diagnostics, the segment delivered 7% organic growth in the quarter. Adjusted EBITDA grew 32% and the adjusted EBITDA margin of 29% was driven by product mix with a higher level of extraction sales. We communicated earlier this year that we entered 2026 with a stronger M&A pipeline, and we see continued improvement in our M&A activities and momentum. We have year-to-date closed four acquisitions and continue to have a very active pipeline going forward as well across all four segments. The latest acquisition is the crematorium business, Verona Pet, within our diagnostic business in Italy. From a sustainability perspective, we continue to deliver our sustainability agenda in our Spring initiative. We received further recognition through the rating upgrade from AA to AAA within MSCI.
We are now among the top 1% of MSCI rated peers globally and a leader among 153 health care equipment and supplies companies.
This concludes the run-through of the quarter, and I will hand over to Kalua for deeper insights into the financials.
Thank you, Jen. And let's jump into the financials. More specifically on the numbers for the second quarter, adjusted EBITDA in the second quarter was €29.7 million, corresponding to an increase of 17%. And that translates into an adjusted EBITDA margin equal to 24.5%. The margin increase compared to the same period last year is primarily a result of positive margin development. In our MedTech dental business, central costs amounted to €3.0 million, an increase from €2.2 million last year. This increase is mainly the result of expenses related to our long-term incentive programs. In total, €0.8 million in the quarter, and during the end of the second quarter, we implemented LTI 26 as approved by the Annual General Meeting in April, where we will see the full effect from the third quarter and onwards. These are non-cash IFRS expenses that will recur for the duration of the three-year programs. We report an operating profit of €22.3 million, a significant 54% increase from last year's result of €14.5 million. Items affecting comparability decreased in the quarter compared to the same period last year and totaled -€0.9 million. The majority of items affecting comparability relates to acquisition costs in Veterinary Services and in Diagnostics, totaling -€0.5 million. Net financial items amounted to -€8.0 million and consisted of three main parts: financing expenses of -€3.1 million, with an average interest rate of 3.9% during the quarter, partly offset by interest income of €0.2 million, a quarterly discounting impact of -€1.0 million, and a negative impact of €2.5 million from probability adjustments related to contingent considerations, mainly relating to new acquisitions. A negative impact of €1.6 million from exchange rate effects on revaluation of debt. Income tax expense for the quarter was -5.5 million, at an effective tax rate of 39% in the quarter. The tax expense as a percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses. In total, this results in a profit for the period of €8.8 million, with an earnings per share of €0.02 for the quarter. Looking at cash flow for the second quarter, cash flow from operating activities reached €3.8 million, and the operating cash flow was negatively impacted by the timing of taxes paid and Net Working Capital effects. Net working capital amounted to €114.1 million at the end of the quarter, equal to 26% of revenue, an increase from €92.8 million at the end of the first quarter, which equaled 21% of revenue. The majority of the €21.3 million increase in working capital relates to increasing receivables after a strong finish to the quarter, as well as specific inventory buildup to support continued customer demand; cash flow from investing activities amounted to -€22.9 million, primarily consisting of acquisitions and earn-out payments. And finally, cash flow from financing activities was €20.5 million from proceeds from borrowings. At the end of the quarter. Net debt amounted to 273.7 million, which is up from 258.4 million at the end of the first quarter. Cash and cash equivalents amounted to 51.6 million, an increase compared to 50.4 million at the end of March, with external lending of 261.7 million at the end of the second quarter. All in all, this resulted in the leverage at the end of the quarter equal to 2.1x, unchanged compared to the end of the first quarter. And we continue to be well capitalized with an ability to execute on our strengthened acquisition pipeline, and with this, I conclude the financial review. I hand the word back to Ali for concluding remarks. Thank you, Juan. Summarizing the first half of 2026, I am pleased to see that improved execution of our key strategic focus areas has been successful. The quarter was strong with double-digit organic revenue growth, strong earnings growth, and improved margins, all well ahead of the global animal health market. We've closed four acquisitions year to date and have a highly active pipeline across all four segments. For the remainder of the year, during the second half, our focus will be on executing our M&A pipeline while continuing to drive strong organic growth and building a strong culture. Thank you for your attention. And with that, we can open up for Q&A.